The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2022 | Looking forward to COMy 2022
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, gives an overview of the main topics that will be discussed at the 8th World Congress on Controversies in Multiple Myeloma (COMy) taking place both in Paris and virtually from May 12-14 2022. Prof. Mohty explains that there will be sessions dedicated to high-risk multiple myeloma as well as myeloma precursor diseases, amyloidosis and Waldenström’s macroglobulinemia. Experts will also discuss advances in immunotherapies for multiple myeloma and give updates on key clinical trials evaluating treatments for this condition. In addition, there will be talks on the management of both young and fit patients and elderly or non-transplant eligible patients with multiple myeloma, as well as on practical considerations for clinicians. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
